Functional Consequences of a SDHB Gene Mutation in an Apparently Sporadic Pheochromocytoma
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Three genes encoding for mitochondrial complex II proteins are linked to hereditary paraganglioma. We have recently shown that an inactivation of the SDHD gene is associated with a complete loss of mitochondrial complex II activity and a stimulation of the angiogenic pathway (Gimenez-Roqueplo, A. P., J. Favier, P. Rustin, J. J. Mourad, P. F. Plouin, P. Corvol, A. Rötig, and X. Jeunemaitre, 2001, Am J Hum Genet 69:1186-1197). Here, we relate the case of a malignant sporadic pheochromocytoma induced by a germline missense mutation of the SDHB gene. Within the tumor, a loss of heterozygosity at chromosome 1pter led to a null SDHB allele and to a complete loss of complex II enzymatic activity. In situ hybridization and immunohistochemistry experiments showed a high expression of hypoxic-angiogenic responsive genes, similar to that previously observed in inherited-SDHD tumors. This observation highlights the role of the complex II mitochondrial genes in the oxygen-sensing pathway and in the regulation of angiogenesis of neural crest-derived tumors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mitochondrial complex II is a component of the electron transport chain, and mutations of SDHB or SDHD genes that abrogate the oxidoreductase function of complex II can cause pheochromocytomas [9,14,15].”
From A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas (2005) · cites this paper as [14]
Citations
Cites
Mutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638 · cited 1×
“The SDHD and SDHC genes were sequenced as previously described (1, 3).”
MethodGerm-Line Mutations in Nonsyndromic Pheochromocytoma
Neumann, H. P. H., Bausch, B., McWhinney, S. R., Bender, B. U., Gimm, O., Franke, G., Schipper, J., Klisch, J., Altehoefer, C., Zerres, K., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020152 · Cited by 1,367
Astuti, D., Latif, F., Dallol, A., Dahia, P. L. M., Douglas, F., George, E., Sköldberg, F., Husebye, E. S., Eng, C., & Maher, E. R. (2001) · The American Journal of Human Genetics · doi:10.1086/321282 · Cited by 1,087
Mutations in SDHC cause autosomal dominant paraganglioma, type 3
Niemann, S., & Müller, U. (2000) · Nature Genetics · doi:10.1038/81551 · Cited by 875
Cellular oxygen sensing by mitochondria: old questions, new insight
Chandel, N. S., & Schumacker, P. T. (2000) · Journal of Applied Physiology · doi:10.1152/jappl.2000.88.5.1880 · Cited by 391
Gimenez-Roqueplo, A.-P., Favier, J., Rustin, P., Mourad, J.-J., Plouin, P.-F., Corvol, P., Rötig, A., & Jeunemaitre, X. (2001) · The American Journal of Human Genetics · doi:10.1086/324413 · Cited by 364 · cited 6×
“The expression of five genes (EPAS1, VEGF, VEGFR-1, VEGFR-2, and neuron-specific enolase) encoding angiogenic and hypoxia-induced factors was studied in SDHB-mutated pheochromocytoma tissue by immunohistochemistry and in situ hybridization with procedures previously described (5, 9).”
BackgroundMethodSelf-citationSuccinate dehydrogenase and fumarate reductase from Escherichia coli
Cecchini, G., Schröder, I., Gunsalus, R. P., & Maklashina, E. (2002) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(01)00238-9 · Cited by 283 · cited 4×
“00/0 The Journal of Clinical Endocrinology & Metabolism 87(10):4771–4774”
BackgroundInfluentialGimm, O., Armanios, M. Y., Dziema, H., Neumann, H. P. H., & Eng, C. (2000) · PubMed · Cited by 274
Germline SDHD mutation in familial phaeochromocytoma
Astuti, D., Douglas, F., Lennard, T. W., Aligianis, I. A., Woodward, E. R., Evans, D. G. R., Eng, C., Latif, F., & Maher, E. R. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04378-6 · Cited by 246 · cited 1×
“catecholamine-secreting pheochromocytomas (5, 6), heredi-”
Enhancement of mRNA in situ hybridization signal by microwave heating.
Sibony, M., Commo, F., Callard, P., & Gasc, J. (1995) · PubMed · Cited by 135
Cited by
Items 101–200 of 217
Clinical Experience with Pheochromocytoma in a Single Centre Over 16 Years
Cotesta, D., Petramala, L., Serra, V., Pergolini, M., Crescenzi, E., Zinnamosca, L., Toma, G. D., Ciardi, A., Carbone, I., Massa, R., et al. (2009) · High Blood Pressure & Cardiovascular Prevention · doi:10.2165/11530430-000000000-00000 · Cited by 37
“It is formed by four exons and codifies for an anchoring protein of 12 kd.([33]) Mutations of this gene are associated with the so-called paraganglioma/pheochromocytoma syndromes that are characterized by the presence of multiple paragangliomas of the head and neck, associated with intra- and extra-adrenal pheochromoc…”
BackgroundA novel G106D alteration of the SDHD gene in a pedigree with familial paraganglioma
Ogawa, K., Shiga, K., Saijo, S., Ogawa, T., Kimura, N., & Horii, A. (2006) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.31444 · Cited by 40
Saito, Y., Ishii, K., Aita, Y., Ikeda, T., Kawakami, Y., Shimano, H., Hara, H., & Takekoshi, K. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1738-3 · Cited by 39
“Our results provide insights into the potential mechanisms underlying the association between mitochondrial dysfunction and phenotypes observed in HPPS with SDHB mutation [6, 7].”
BackgroundInfluentialHigh-frequency actionable pathogenic exome variants in an average-risk cohort
Rego, S. M., Dagan‐Rosenfeld, O., Zhou, W., Sailani, M. R., Limcaoco, P., Colbert, E., Avina, M., Wheeler, J., Craig, C. M., Salins, D. N., et al. (2018) · Molecular Case Studies · doi:10.1101/mcs.a003178 · Cited by 38
Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma
Vícha, A., Taïeb, D., & Pacák, K. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0398 · Cited by 37
“…found relatively more common HIF2a overexpression in VHL PHEOs and PGLs, whereas in SDHx-related tumors nuclear HIF1a staining was more prominent, Gimenez-Roqueplo et al. (2001, 2002) described overexpression of HIF2a and VEGF in patients with PHEOs and PGLs carrying SDHB and SDHD mutations…”
Hypotension in a Woman with a Metastatic Dopamine-Secreting Carotid Body Tumor
Koch, C. A., Rodbard, J. S., Brouwers, F. M., Eisenhofer, G., & Pacák, K. (2003) · Endocrine Practice · doi:10.4158/ep.9.4.310 · Cited by 35
Genetic Testing for Pheochromocytoma-associated Syndromes
Pawlu, C., Bausch, B., Reisch, N., & Neumann, H. P. H. (2005) · Annales d Endocrinologie · doi:10.1016/s0003-4266(05)81749-4 · Cited by 36
“The expression of hypoxic-angiogenic responsive genes was found in SDH mutations [19, 20], and may indicate a pathophysiology related to the models of VHL disease.”
BackgroundOxygen Concentration Controls Epigenetic Effects in Models of Familial Paraganglioma
Her, Y. F., Nelson-Holte, M. H., & Maher, L. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127471 · Cited by 35
“It has been reported that SDHB protein loss accompanies any disruption of the SDH complex in PGLs [43,44].”
BackgroundInfluentialFliedner, S. M. J., Kaludercic, N., Jiang, X.-S., Hansíková, H., Hájková, Z., Sládková, J., Limpuangthip, A., Backlund, P. S., WESLEY, R. A., Martiniova, L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040949 · Cited by 36
“First, its function as complex II in the electron transfer chain of the OXPHOS is impaired, resulting in decreased activity in SDHB and D [15,16,17,18], and possibly in A and C, mutations.”
BackgroundFamilial syndromes associated with neuroendocrine tumours
Gut, P., Komarowska, H., Czarnywojtek, A., Waligórska‐Stachura, J., Bączyk, M., Ziemnicka, K., Fischbach, J., Wrotkowska, E., & Ruchała, M. (2015) · Współczesna Onkologia · doi:10.5114/wo.2015.52710 · Cited by 33
Zhang, D., Wang, W., Xiang, B., Li, N., Huang, S., Zhou, W., Sun, Y., Wang, X., Ma, J., Li, G., et al. (2013) · Tumor Biology · doi:10.1007/s13277-013-0781-4 · Cited by 36
Pai, R. B., Manipadam, M. T., Singh, P., Ebenazer, A., Samuel, P., & Rajaratnam, S. (2014) · Apmis · doi:10.1111/apm.12269 · Cited by 33
Genetic Testing in Pheochromocytoma‐ and Paraganglioma‐Associated Syndromes
Benn, D. E., Richardson, A. L., Marsh, D. J., & Robinson, B. G. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1353.011 · Cited by 36
Active succinate dehydrogenase (SDH) and lack of SDHD mutations in sporadic paragangliomas.
Braun, S., Riemann, K., Kupka, S., Leistenschneider, P., Sotlar, K., Schmid, H., & Blin, N. (2005) · PubMed · Cited by 38
Pathophysiology and Diagnosis of Disorders of the Adrenal Medulla: Focus on Pheochromocytoma
Lenders, J. W. M., & Eisenhofer, G. (2014) · Comprehensive physiology · doi:10.1002/cphy.c130034 · Cited by 32
Castellano, M., Mori, L., Giacchè, M., Agliozzo, E., Tosini, R., Panarotto, A., Cappelli, C., Mulatero, P., Cumetti, D., Veglio, F., et al. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1353.016 · Cited by 30
Jugulotympanic paragangliomas: 75 years of evolution in understanding
Forbes, J. A., Brock, A. A., Ghiassi, M., Thompson, R. C., Haynes, D. S., & Tsai, B. S. (2012) · Neurosurgical FOCUS · doi:10.3171/2012.6.focus12138 · Cited by 29
Lima, J. P., Teixeira-Gomes, J., Soares, P., Máximo, V., Honavar, M., Williams, E. D., & Sobrinho-Simões, M. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-030008 · Cited by 30
Rapizzi, E., Ercolino, T., Canu, L., Giaché, V., Francalanci, M., Pratesi, C., Valeri, A., & Mannelli, M. (2012) · Endocrine Related Cancer · doi:10.1530/erc-11-0263 · Cited by 31
“In particular, Gimenez-Roqueplo et al. (2001) reported that in a French family, a mutation in SDHD results in the lack of SDH activity, and they also found a loss of SDH activity in two patients with SDHB and SDHA mutations (Gimenez-Roqueplo et al. 2002, Burnichon et al. 2010).”
BackgroundLips, C. J. M., Lentjes, E. G. W. M., Höppener, J. W. M., van der Luijt, R. B., & Moll, F. L. (2006) · Hereditary Cancer in Clinical Practice · doi:10.1186/1897-4287-4-4-169 · Cited by 30
“Preferably, suspected lymph nodes on the side of the paraganglioma have to be removed during surgery, even if the risk is small that metastases are present [18-20].”
BackgroundMolecular Genetic Alterations in Adrenal and Extra-Adrenal Pheochromocytomas and Paragangliomas
Dannenberg, H., Komminoth, P., Dinjens, W. N. M., Speel, E. M., & de Krijger, R. R. (2003) · Endocrine Pathology · doi:10.1385/ep:14:4:329 · Cited by 34
Maier-Woelfle, M., Brändle, M., Komminoth, P., Saremaslani, P., Schmid, S., Locher, T., Heitz, P. U., Krull, I., Galeazzi, R. L., Schmid, C., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031236 · Cited by 28
“(16) have shown LOH in tumor tissue of a SDHB-associated PCC.”
BackgroundLoss of SDHB Induces a Metabolic Switch in the hPheo1 Cell Line toward Enhanced OXPHOS
Tabebi, M., Dutta, R. K., Skoglund, C., Söderkvist, P., & Gimm, O. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010560 · Cited by 29
Malignant Paraganglioma of the Urinary Bladder: Immunohistochemical Study of Prognostic Indicators
Kovács, K., Bell, D., Gardiner, G. W., Honey, R. J. D., Goguen, J., & Rotondo, F. (2005) · Endocrine Pathology · doi:10.1385/ep:16:4:363 · Cited by 26
Pheochromocytoma-associated syndromes: genes, proteins and functions of RET, VHL and SDHx
Gimm, O. (2005) · Familial Cancer · doi:10.1007/s10689-004-5740-1 · Cited by 26
“Functional analysis confirmed that inactivation of cybS abolishes the enzymatic activity of mitochondrial complex II and activates the hypoxia pathway (e.g., through increased expression of VEGF) [ 58 ].”
BackgroundMolecular imaging of adrenal neoplasms
Chen, C. C., & Carrasquillo, J. A. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23162 · Cited by 25
“These findings are likely related to up regulation of hypoxic angiogenic responsive genes in patients with SDHx mutations [56].”
BackgroundCircadian rhythm disruption and endocrine-related tumors
Savvidis, C., Kallistrou, E., Kouroglou, E., Dionysopoulou, S., Gavriiloglou, G., Ragia, D., Tsiama, V., Proikaki, S., Belis, K., & Ilias, Ι. (2024) · World Journal of Clinical Oncology · doi:10.5306/wjco.v15.i7.818 · Cited by 24
Weber, A., Hoffmann, M. M., Neumann, H. P. H., & Erlic, Z. (2012) · Hormones and Cancer · doi:10.1007/s12672-012-0113-y · Cited by 24
Glutaminases as a Novel Target for SDHB-Associated Pheochromocytomas/Paragangliomas
Sarkadi, B., Meszaros, K., Krencz, I., Canu, L., Krokker, L., Zakarias, S., Barna, G., Sebestyen, A., Papay, J., Hujber, Z., et al. (2020) · Cancers · doi:10.3390/cancers12030599 · Cited by 23
Neurotransmitter CART as a New Therapeutic Candidate for Parkinson’s Disease
Mao, P., Meshul, C. K., Thuillier, P., & Reddy, P. (2013) · Pharmaceuticals · doi:10.3390/ph6010108 · Cited by 24
Marzola, M. C., Chondrogiannis, S., Grassetto, G., Rampin, L., Maffione, A. M., Ferretti, A., Opocher, G., Schiavi, F., Colletti, P. M., & Rubello, D. (2013) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e31829aface · Cited by 23
New Advances in the Genetics of Pheochromocytoma and Paraganglioma Syndromes
Gimenez‐Roqueplo, A. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1353.012 · Cited by 25
Self-citationA SDHB malignant paraganglioma with dramatic response to temozolomide–capecitabine
Nozières, C., Walter, T., Joly, M., Giraud, S., Scoazec, J., Borson‐Chazot, F., Simon, C., Riou, J. P., & Lombard‐Bohas, C. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-1098 · Cited by 22
Pheochromocytomas and Paragangliomas—Current Management
Brewczyński, A., Kolasińska, A. D., Jabłońska, B., & Wyrwicz, L. S. (2025) · Cancers · doi:10.3390/cancers17061029 · Cited by 22
Loss of sdhb in zebrafish larvae recapitulates human paraganglioma characteristics
Dona, M., Waaijers, S., Richter, S., Eisenhofer, G., Korving, J., Kamel, S. M., Bakkers, J., Rapizzi, E., Rodenburg, R. J., Zethof, J., et al. (2020) · Endocrine Related Cancer · doi:10.1530/erc-20-0308 · Cited by 22
Pediatric paraganglioma: An early manifestation of an adult disease secondary to germline mutations
Mora, J., Cascón, A., Robledo, M., & Català, A. (2005) · Pediatric Blood & Cancer · doi:10.1002/pbc.20680 · Cited by 21
“Gimenez and coworkers [8,9] have described the immediate consequences in the tumoral tissue of SDHD and SDHB mutations.”
BackgroundMcDonnell, C. M., Benn, D. E., Marsh, D. J., Robinson, B. G., & Zacharin, M. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02122.x · Cited by 23
Smestad, J. A., Hamidi, O., Wang, L., Holte, M. N., Khazal, F. J. A., Erber, L. N., Chen, Y., & Maher, L. J. (2017) · Oncotarget · doi:10.18632/oncotarget.23639 · Cited by 21
Gupta, P., Strange, K., Telange, R., Guo, A., Hatch, H. M., Sobh, A., Elie, J., Carter, A. M., Totenhagen, J. W., Tan, C., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111218 · Cited by 18
Novel Hereditary Forms of Pheochromocytomas and Paragangliomas
Dahia, P. L. M. (2013) · Frontiers of hormone research · doi:10.1159/000345671 · Cited by 18
Ishii, T., Yasuda, K., Miyazawa, M., Mitsushita, J., Johnson, T. E., Hartman, P. S., & Ishii, N. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.02.013 · Cited by 16
“…and colleagues studied the biological effects of a loss-of-function SDHD germline mutation (p.Arg22X) in an extra-adrenal PGL and a missense SDHB germline mutation (p.Arg46Gln) in a malignant PHEO with a somatic terminal deletion of 1p (Gimenez-Roqueplo et al., 2001; Gimenez-Roqueplo et al., 2002).”
BackgroundSporadic paraganglioma caused by de novo SDHB mutations in a 6-year-old girl
Imamura, H., Muroya, K., Tanaka, E., Konomoto, T., Moritake, H., SATO, T. A., Kimura, N., Takekoshi, K., & Nunoi, H. (2015) · European Journal of Pediatrics · doi:10.1007/s00431-015-2614-5 · Cited by 17
“regulation of the hypoxia pathway including overexpression of hypoxia-inducible factor alpha (HIF-α) and hypoxiainducible gene products [5, 8, 16].”
BackgroundEng, C. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn263 · Cited by 16
Hypoxia signaling pathway: A central mediator in endocrine tumors
Watts, D., Jaykar, M. T., Bechmann, N., & Wielockx, B. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1103075 · Cited by 17
“Thus, HIF-2a inhibitors are potentially more promising compared to HIF-1a inhibitors for the treatment of endocrine tumors, especially PCCs and PGLs.”
BackgroundInfluentialOxidative Phosphorylation Dysfunction Modifies the Cell Secretome
Garrido-Pérez, N., Vela‐Sebastián, A., López‐Gallardo, E., Emperador, S., Iglesias, E., Meade, P., Jimenez-Mallebrera, C., Montoya, J., Bayona‐Bafaluy, M. P., & Ruiz‐Pesini, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093374 · Cited by 16
“Increased VEGF mRNA expression, and stimulation of the angiogenic pathway, were found in paraganglioma and pheochromocytoma tumors carrying mutations in nDNA-encoded CII subunits SDHB and SDHD that result in decreased CII activity [73,74].”
Background15 YEARS OF PARAGANGLIOMA: Metabolism and pheochromocytoma/paraganglioma
Mannelli, M., Rapizzi, E., Fucci, R., Canu, L., Ercolino, T., Luconi, M., & Young, W. F. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0215 · Cited by 15
Pheochromocytoma: When to search a germline defect?
Buffet, A., Burnichon, N., Amar, L., & Gimenez‐Roqueplo, A. (2018) · La Presse Médicale · doi:10.1016/j.lpm.2018.07.003 · Cited by 14
Self-citationOxidative phosphorylation inducers fight pathological angiogenesis
Bayona‐Bafaluy, M. P., Esteban, O., Ascaso, J., Montoya, J., & Ruiz‐Pesini, E. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.03.014 · Cited by 14
Kodama, H., Iihara, M., Nissato, S., Isobe, K., Kawakami, Y., Okamoto, T., & Takekoshi, K. (2010) · Endocrine Journal · doi:10.1507/endocrj.k09e-324 · Cited by 14
“Current evidence suggests that mutations in SDHB are frequently associated with abdominal paraganglioma and the following distant metastasis [3-9].”
BackgroundInfluentialZuo, L., Chen, Z., Chen, L., Kang, J., Shi, Y., Liu, L., Zhang, S., Jia, Q., Huang, Y., & Sun, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.750794 · Cited by 14
Lenvatinib as a Therapeutic Option in Unresectable Metastatic Pheochromocytoma and Paragangliomas
Nelson, L. J. H., Fuentes, H. E., Yin, J., Asmus, E. J., Ryder, M. M., Morris, J. C., Hilger, C. R., Bible, K. C., Chintakuntlawar, A. V., & Rao, S. N. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac044 · Cited by 15
“These mutations inactivate the SDH enzyme, leading to an accumulation of succinate and consequently inducing a pseudohypoxic state; this, in turn, increases the expression of VEGF and other angiogenic factors [13-17].”
BackgroundA case of familial paraganglioma syndrome type 4 caused by a mutation in the SDHB gene
Drucker, A. M., & Houlden, R. L. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0342 · Cited by 14
Igaz, P., Wiener, Z., Szabó, P. M., Falus, A., Gaillard, R. C., Horányi, J., Rácz, K., & Tulassay, Z. (2006) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2006.06.011 · Cited by 13
Aim, L. B., Maher, E. R., Cascón, A., Barlier, A., Giraud, S., Ercolino, T., Pigny, P., Clifton-Bligh, R. J., Mirebeau‐Prunier, D., Mohamed, A., et al. (2021) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2020-107652 · Cited by 12
Self-citationKato, M., Maeda, K., Nakahara, R., Hirose, H., Kondo, A., Aki, S., Sugaya, M., Hibino, S., Nishida, M., Hasegawa, M., et al. (2023) · PNAS Nexus · doi:10.1093/pnasnexus/pgad306 · Cited by 13
Takekoshi, K., Isobe, K., Suzuki, H., Nissato, S., Kawakami, Y., Kawai, K., & Yamada, N. (2008) · Endocrine Journal · doi:10.1507/endocrj.k07-087 · Cited by 12
“female patient with a large, highly vascularized adrenal tumor, which extended into the heart with multiple pulmonary metastases [3].”
BackgroundHypoxia Signaling and Circadian Disruption in and by Pheochromocytoma
Tabebi, M., Söderkvist, P., & Jensen, L. D. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00612 · Cited by 12
“SDHx mutations increase the stability of HIFs and the expression of their targets (15, 30).”
BackgroundInfluentialSaito, T., Saito, Y., Matsumura, K., Tsubota, Y., Maniwa, T., Kaneda, H., Minami, K.-I., Sakaida, N., Uemura, Y., Kawa, G., et al. (2009) · Endocrine Journal · doi:10.1507/endocrj.k08e-178 · Cited by 11
Failure of MIBG scan to detect metastases in SDHB‐mutated pediatric metastatic pheochromocytoma
Sait, S. F., Pandit-Taskar, N. D., & Modak, S. I. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26549 · Cited by 11
The malignant potential of a succinate dehydrogenase subunit B germline mutation
Gómez, C. F., Menéndez, E., Pineda, J. J., de Esteban, J. P. M., Anda, E., Goñi, M. J., Bausch, B., & Neumann, H. P. H. (2006) · Journal of Endocrinological Investigation · doi:10.1007/bf03344107 · Cited by 11
Endoglin as a marker in cervical paragangliomas
Eleno, N., Düwel, A., Muñoz, A., Paz-Bouza, J. I., López-Novoa, J. M., & Lozano, F. S. (2009) · Head & Neck · doi:10.1002/hed.21248 · Cited by 11
“Although there are no reports about HIF in CPG, 1 of the best known genetic defects associated with paragangliomas are mutations of subunits of succinate dehydrogenase; these defects result in a dysfunction of the enzymatic activity in the complex II of the mitochondrial respiratory chain with activation of the hypoxi…”
BackgroundAnalysis of PTEN Mutation in Non‐familial Pheochromocytoma
Puc, J., Placha, G., Wocial, B., Podsypanina, K., Parsons, R. E., & Gaciong, Z. A. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1353.037 · Cited by 10
Jochmanová, I., & Lazúrová, I. (2014) · Biomedical Papers · doi:10.5507/bp.2014.021 · Cited by 10
Primary Malignant Hepatic Pheochromocytoma with Negative Adrenal Scintigraphy
Homma, K., Hayashi, K., Wakino, S., Irie, R., Mukai, M., Kumagai, H., Shibata, H., & Saruta, T. (2006) · Hypertension Research · doi:10.1291/hypres.29.551 · Cited by 10
p53 Alterations and Their Relationship to SDHD Mutations in Parasympathetic Paragangliomas
van Nederveen, F. H., Dannenberg, H., Sleddens, H. F. B. M., de Krijger, R. R., & Dinjens, W. N. M. (2003) · Modern Pathology · doi:10.1097/01.mp.0000084111.03922.4d · Cited by 11
“A complete loss of complex II enzymatic activity, due to inactivating mutations in the SDHB, SDHC, or SDHD gene and loss of heterozygosity of the corresponding wild type allele, leads to a high expression of hypoxicangiogenic responsive genes like vascular endothelial growth factor (VEGF) and endothelial periodic acid…”
Maher, E. R. (2006) · British Medical Bulletin · doi:10.1093/bmb/ldl002 · Cited by 9
Metabolism of Cell Growth and Proliferation
DeBerardinis, R. J., & Thompson, C. B. (2008) · Elsevier eBooks · doi:10.1016/b978-141603703-3.10014-7 · Cited by 11
Milione, M., Pusceddu, S., Gasparini, P., Melotti, F., Maisonneuve, P., Mazzaferro, V., de Braud, F., & Pelosi, G. (2012) · Cancers · doi:10.3390/cancers4030808 · Cited by 7
“is a highly conserved heterotetrameric protein, with SDHA and SDHB functioning as catalytic subunits, which protrudes into the mitochondrial matrix and is anchored to the inner membrane by means of SDHC and SDHD subunits, the latter also providing the binding site for ubiquinone [15–40].”
BackgroundFamilial Paragangliomas: Case Report and Literature Review
Vijan, S. S., Ibrahim, Z., Thompson, G. B., Schaff, H. V., & Young, W. F. (2008) · Endocrine Practice · doi:10.4158/ep.14.5.603 · Cited by 6
Pheochromocytoma: Unmasking the Chameleon
Robles, J., MERCADO-ASIS, L. B., & Pacák, K. (2012) · Humana Press eBooks · doi:10.1007/978-1-60761-548-4_7 · Cited by 6
Ishii, T., Yasuda, K., Miyazawa, M., Onouchi, H., Yanase, S., & Ishii, N. (2025) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.25-62 · Cited by 5
“(13) They also constitute 29% of pediatric cases, 38% of malignant tumors and more than 80% of familial aggregations of PHEO and PGL. (14) The inactivation of SDH activity resulting in succinate accumulation leads to inhibit prolyl-hydroxylation of hypoxia inducible factors (HIF)-1alpha (HIF-1a),…”
Heritable and Syndromic Pheochromocytoma and Paraganglioma
Kopp, P. A. (2018) · Contemporary Endocrinology · doi:10.1007/978-3-319-77048-2_4 · Cited by 5
Pacák, K., Timmers, H. J. L. M., & Eisenhofer, G. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00110-4 · Cited by 5
Sato, H., Kanai, G., Hirabayshi, K., Kajiwara, H., Itoh, J., & OSAMURA, R. Y. (2010) · Endocrine · doi:10.1007/s12020-010-9365-x · Cited by 5
Prasad, P. K., Kant, J. A., Wills, M. L., O’Leary, M. F., Lovvorn, H. N., & Yang, E. (2009) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2009.04.009 · Cited by 6
“LOH in SDHB tumors has been demonstrated by fluorescence in situ hybridization by using probes for chromosome 1 p in a nonfamilial malignant pheochromocytoma [10].”
Neuroendocrine Neoplasms, Olfactory Neuroblastomas and Paragangliomas of the Head and Neck
Klöppel, G., Franchi, A., & Matías‐Guiu, X. (2016) · Springer eBooks · doi:10.1007/978-3-662-49672-5_11 · Cited by 5
Angiogenic and anti-angiogenic factors in adrenal tumours.
Jurczyńska, J., Zieleniewski, W., Stepien, H., & Komorowski, J. (2006) · PubMed · Cited by 5
High Frequency Actionable Pathogenic Exome Mutations in an Average-Risk CohortPreprint
Rego, S. M., Dagan‐Rosenfeld, O., Zhou, W., Sailani, M. R., Limcaoco, P., Colbert, E., Avina, M., Wheeler, J., Craig, C. M., Salins, D. N., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/151225 · Cited by 5
“2016) PS4 (Gimenez-Roqueplo et al. 2002; Benn et al. 2003; Kimura et al. 2014) PP3 PP5 APC (2) Dominant NM_001127510 c.”
Molecular Imaging in Hereditary Succinate Dehydrogenase Mutation–Related Paragangliomas
Marzola, M. C., & Rubello, D. (2014) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000000572 · Cited by 4
“First, chronic hypoxia in the cells can favor the gene alteration, especially in the case of SDH-D mutation.(17,18) Second, in fetal life, extraadrenal paraganglionic tissue tends to degenerate after birth via cell apoptosis related to a reduction of nerve growth factor.”
BackgroundACN9 Regulates the Inflammatory Responses in Human Bronchial Epithelial Cells
Jeong, J. H., Kim, J., Kim, J., Heo, H.-R., Jeong, J. S., Ryu, Y.-J., Hong, Y., Han, S., Hong, S., Lee, S., et al. (2017) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2017.80.3.247 · Cited by 4
Génétique des tumeurs endocrines
Calender, A., Dupasquier, S., Cordier–Bussat, M., & Zhang, C. X. (2005) · Annales de Pathologie · doi:10.1016/s0242-6498(05)86161-9 · Cited by 4
Genetic-clinical profile of subjects with apparently sporadic extra-adrenal paragangliomas
Ramundo, V., Ercolino, T., Faggiano, A., Giachè, V., Ragghianti, B., Rapizzi, E., Colao, A., & Mannelli, M. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00065 · Cited by 3
“SDHB mutations (PGL-4) are mainly associated with extra-adrenal abdominal or thoracic secreting PGLs (sPGLs; Gimenez-Roqueplo et al., 2002; Neumann et al., 2004; Amar et al., 2005; Benn et al., 2006).”
BackgroundPacák, K., Timmers, H. J. L. M., & Eisenhofer, G. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00109-x · Cited by 8
Zhang, J., Tang, Z., Wang, Y., Wan, J., Zhou, Y., Li, J., & Ming, J. (2026) · Cells · doi:10.3390/cells15151422 · Cited by 3
Baio, R., Pagano, T., Molisso, G., Mauro, U. D., Intilla, O., Albano, F., Scarpato, F., Giacometti, S., & Sanseverino, R. C. (2022) · Diseases · doi:10.3390/diseases10020029 · Cited by 2
“The gene for the SDHD, located in chromosome 11, codifies for an anchoring protein [24].”
BackgroundApports de COMETE à la génétique du phéochromocytome
Gimenez‐Roqueplo, A., Burnichon, N., Amar, L., Favier, J., Jeunemaître, X., & Plouin, P. (2008) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)32851-1 · Cited by 4
Self-citationParaganglioma and Pheochromocytoma
Iacobone, M., & Torresan, F. (2021) · Springer eBooks · doi:10.1007/978-3-030-62241-1_15 · Cited by 2
Molecular Biology of Pheochromocytomas and Paragangliomas
King, E. E., & Dahia, P. L. M. (2009) · Springer eBooks · doi:10.1007/978-1-4419-1069-1_13 · Cited by 2
“SDH comprises four subunits, A, B, C, and D. Subunits A and B represent the catalytic portion of complex II, while subunits C and D anchor the complex to the mitochondrial membrane [ 37 ].”
BackgroundHubalewska–Dydejczyk, A., Timmers, H. J. L. M., & Trofimiuk–Müldner, M. (2015) · Wiley eBooks · doi:10.1002/9781119031659.ch10 · Cited by 1
Timmers, H. J. L. M., & Pacák, K. (2007) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2.3.399 · Cited by 1
Shand, J. A. D., van Schalkwyk, J., Beavis, V. S., Niyagama, A., Taylor, S., & Eagleton, C. L. (2022) · Internal Medicine Journal · doi:10.1111/imj.15965 · Cited by 2
“20,23 In individuals harbouring a germline SDHB pathogenic variant, the remaining wild-type SDHB allele is capable of producing suf fi cient functional protein to allow normal TCA and ETC function.”
BackgroundRadionuclide Imaging of Pheochromocytoma and Paraganglioma in the Era of Multi-omics
Timmers, H. J. L. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-46038-3_12 · Cited by 1
The Pathogenesis of Pheochromocytomas: Of Mice and Men
Korpershoek, E. (2011) · EUR Research Repository (Erasmus University Rotterdam) · Cited by 1
New imaging approaches to phaeochromocytomas and paragangliomas
Dullaart, R. P. F., van der Horst‐Schrivers, A. N. A., & Koopmans, K. P. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03705.x · Cited by 1
From chromaffin cells to Phaeochromocytoma: insight into the sympathoadrenal cell lineage
Cleary, S. (2007) · Murdoch University Research Portal
Mutations de gènes impliqués dans le métabolisme énergétique et cancer
Thibault, C., & Gimenez‐Roqueplo, A. (2013) · ONCOLOGIE · doi:10.1007/s10269-013-2320-8
“L’ensemble de ces mutations semble avoir les mêmes conséquences fonctionnelles, à savoir la désintégration du complexe II mitochondrial et la perte de l’activité enzymatique SDH aboutissant à l’accumulation de succinate dans la mitochondrie et dans le cytosol [17,18,54].”
BackgroundSelf-citationEndocrine Neoplasia in Childhood
Blair, J. (2009) · Wiley eBooks · doi:10.1002/9781444316728.ch17
Mitochondrial Complex II in Cancer
Kľučková, K., Neužil, J., & Rohlena, J. (2014) · Springer eBooks · doi:10.1007/978-94-017-8984-4_4
Pediatric Paragangliomas: Role of Germline Mutation in Succinate Dehydrogenase
Prasad, P. K., & Yang, E. (2012) · Pediatric cancer · doi:10.1007/978-94-007-2957-5_30
The enzyme succinate dehydrogenase (SDH) and its role in hereditary pituitary adenomas
Панкратова, Ю. В., Przhiyalkovskaya, E. G., Pigarova, E. A., & Dzeranova, L. K. (2013) · Obesity and metabolism · doi:10.14341/omet2013410-15
Metadata
- Authors
- Gimenez-Roqueplo, A.-P., Favier, J., Rustin, P., Rieubland, C., Kerlan, V., Plouin, P.-F., Rötig, A., & Jeunemaitre, X.
- Affiliations
- Inserm (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2002-10
- Volume
- 87
- Issue
- 10
- Pages
- 4771-4774
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2144878030
- Cited by
- 209
- References
- 13
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 5 · 2022: 7 · 2021: 6 · 2020: 5 · 2019: 4 · 2018: 7 · 2017: 5 · 2016: 6 · 2015: 14 · 2014: 15 · 2013: 13 · 2012: 15
- FWCI
- 10.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Keywords
- sporadic pheochromocytoma, succinate dehydrogenase, loss of heterozygosity, hypoxia-inducible factor, angiogenesis, oxygen sensing, neural crest-derived tumors, hereditary paraganglioma, germline missense mutation, tumor suppressor
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Adrenal Gland Neoplasms, Chromosomes, Human, Pair 1, DNA Mutational Analysis, Female, Humans, Immunohistochemistry, Iron-Sulfur Proteins, Lymphokines, Middle Aged, Multienzyme Complexes, Mutation, Oxidoreductases, Pheochromocytoma, RNA, Messenger, Succinate Dehydrogenase, Tomography, X-Ray Computed, Trans-Activators, Gene Expression, Endothelial Growth Factors, In Situ Hybridization, Sequence Analysis, DNA, Germ-Line Mutation, Loss of Heterozygosity, Mutation, Missense, Protein Subunits, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Electron Transport Complex II, Basic Helix-Loop-Helix Transcription Factors, Basic Helix-Loop-Helix Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.